GlassScriptPhysician profile
Anamika Tandon
NPI 1356720072
$1,218.46
in general payments reported to CMS, 2019-2025
21 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $243 · 2022: $253 · 2023: $325 · 2024: $241 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $278.81 | 2021-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $248.96 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Horizon Therapeutics Plc | $145.81 | 2022-2023 | Procysbi |
| Gilead Sciences, INC. | $97.13 | 2021 | |
| Pfizer INC. | $71.30 | 2023-2024 | |
| Boston Scientific Corporation | $55.79 | 2021-2022 | |
| Csl Behring | $37.24 | 2023-2024 | Kcentra |
| Regeneron Healthcare Solutions, INC. | $27.83 | 2024 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $27.40 | 2025 | Opsumit |
| Amgen INC. | $27.16 | 2023-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.97 | 2024 | Ofev |
| United Therapeutics Corporation | $23.35 | 2024 | Tyvaso |
| Ethicon INC. | $22.47 | 2022 | |
| Exact Sciences Corporation | $22.23 | 2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $19.75 | 2025 | Ozempic |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $16.76 | 2024 | |
| Janssen Biotech, INC. | $16.09 | 2022 | |
| Baxter Healthcare | $14.18 | 2024 | Hillrom - Monarch Airway Clearance System |
| Lilly USA, LLC | $13.97 | 2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $13.94 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.32 | 2023 | Glassia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anamika Tandon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.